News
Jazz Pharmaceuticals’ epilepsy drug advances into phase 3 trial
The phase 3 trials will assess Epidiolex over 14 weeks in a randomised, double-blind, placebo-controlled study, enrolling paediatric patients aged one to 18.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The phase 3 trials will assess Epidiolex over 14 weeks in a randomised, double-blind, placebo-controlled study, enrolling paediatric patients aged one to 18.